A Comparison of Ketamine and Midazolam as First-Line Anesthetic Infusions for Pediatric Status Epilepticus.
Pediatric neurocritical care
Pediatric refractory status epilepticus
Pediatric status epilepticus
Pediatric superrefractory status epilepticus
Journal
Neurocritical care
ISSN: 1556-0961
Titre abrégé: Neurocrit Care
Pays: United States
ID NLM: 101156086
Informations de publication
Date de publication:
02 Oct 2023
02 Oct 2023
Historique:
received:
07
07
2023
accepted:
08
09
2023
pubmed:
3
10
2023
medline:
3
10
2023
entrez:
2
10
2023
Statut:
aheadofprint
Résumé
Pediatric refractory status epilepticus (RSE) often requires management with anesthetic infusions, but few data compare first-line anesthetics. This study aimed to compare the efficacy and adverse effects of midazolam and ketamine infusions as first-line anesthetics for pediatric RSE. Retrospective single-center study of consecutive study participants treated with ketamine or midazolam as the first-line anesthetic infusions for RSE at a quaternary care children's hospital from December 1, 2017, until September 15, 2021. We identified 117 study participants (28 neonates), including 79 (68%) who received midazolam and 38 (32%) who received ketamine as the first-line anesthetic infusions. Seizures terminated more often in study participants administered ketamine (61%, 23/38) than midazolam (28%, 22/79; odds ratio [OR] 3.97, 95% confidence interval [CI] 1.76-8.98; P < 0.01). Adverse effects occurred more often in study participants administered midazolam (24%, 20/79) than ketamine (3%, 1/38; OR 12.54, 95% CI 1.61-97.43; P = 0.016). Study participants administered ketamine were younger, ketamine was used more often for children with acute symptomatic seizures, and midazolam was used more often for children with epilepsy. Multivariable logistic regression of seizure termination by first-line anesthetic infusion (ketamine or midazolam) including age at SE onset, SE etiology category, and individual seizure duration at anesthetic infusion initiation indicated seizures were more likely to terminate following ketamine than midazolam (OR 4.00, 95% CI 1.69-9.49; P = 0.002) and adverse effects were more likely following midazolam than ketamine (OR 13.41, 95% CI 1.61-111.04; P = 0.016). Survival to discharge was higher among study participants who received midazolam (82%, 65/79) than ketamine (55%, 21/38; P = 0.002), although treating clinicians did not attribute any deaths to ketamine or midazolam. Among children and neonates with RSE, ketamine was more often followed by seizure termination and less often associated with adverse effects than midazolam when administered as the first-line anesthetic infusion. Further prospective data are needed to compare first-line anesthetics for RSE.
Sections du résumé
BACKGROUND
BACKGROUND
Pediatric refractory status epilepticus (RSE) often requires management with anesthetic infusions, but few data compare first-line anesthetics. This study aimed to compare the efficacy and adverse effects of midazolam and ketamine infusions as first-line anesthetics for pediatric RSE.
METHODS
METHODS
Retrospective single-center study of consecutive study participants treated with ketamine or midazolam as the first-line anesthetic infusions for RSE at a quaternary care children's hospital from December 1, 2017, until September 15, 2021.
RESULTS
RESULTS
We identified 117 study participants (28 neonates), including 79 (68%) who received midazolam and 38 (32%) who received ketamine as the first-line anesthetic infusions. Seizures terminated more often in study participants administered ketamine (61%, 23/38) than midazolam (28%, 22/79; odds ratio [OR] 3.97, 95% confidence interval [CI] 1.76-8.98; P < 0.01). Adverse effects occurred more often in study participants administered midazolam (24%, 20/79) than ketamine (3%, 1/38; OR 12.54, 95% CI 1.61-97.43; P = 0.016). Study participants administered ketamine were younger, ketamine was used more often for children with acute symptomatic seizures, and midazolam was used more often for children with epilepsy. Multivariable logistic regression of seizure termination by first-line anesthetic infusion (ketamine or midazolam) including age at SE onset, SE etiology category, and individual seizure duration at anesthetic infusion initiation indicated seizures were more likely to terminate following ketamine than midazolam (OR 4.00, 95% CI 1.69-9.49; P = 0.002) and adverse effects were more likely following midazolam than ketamine (OR 13.41, 95% CI 1.61-111.04; P = 0.016). Survival to discharge was higher among study participants who received midazolam (82%, 65/79) than ketamine (55%, 21/38; P = 0.002), although treating clinicians did not attribute any deaths to ketamine or midazolam.
CONCLUSIONS
CONCLUSIONS
Among children and neonates with RSE, ketamine was more often followed by seizure termination and less often associated with adverse effects than midazolam when administered as the first-line anesthetic infusion. Further prospective data are needed to compare first-line anesthetics for RSE.
Identifiants
pubmed: 37783824
doi: 10.1007/s12028-023-01859-2
pii: 10.1007/s12028-023-01859-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023. Springer Science+Business Media, LLC, part of Springer Nature and Neurocritical Care Society.
Références
Daniels ZS, Srdanovic N, Rychlik K, Smith C, Goldstein J, George AL. High-dose midazolam for pediatric refractory status epilepticus: a single-center retrospective study. Pediatr Crit Care Med. 2022;23(11):929–35. https://doi.org/10.1097/PCC.0000000000003043 .
doi: 10.1097/PCC.0000000000003043
pubmed: 35894600
Zaccara G, Giannasi G, Oggioni R, Rosati E. Challenges in the treatment of convulsive status epilepticus. Seizure. 2017;47:17–24. https://doi.org/10.1016/j.seizure.2017.02.015 .
doi: 10.1016/j.seizure.2017.02.015
pubmed: 28282553
Hirsch LJ, Gaspard N, van Baalen A, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia. 2018;59(4):739–44. https://doi.org/10.1111/epi.14016 .
doi: 10.1111/epi.14016
pubmed: 29399791
Vossler DG, Bainbridge JL, Boggs JG, et al. Treatment of refractory convulsive status epilepticus: a comprehensive review by the American Epilepsy Society Treatments Committee. Epilepsy Curr. 2020;20(5):245–64. https://doi.org/10.1177/1535759720928269 .
doi: 10.1177/1535759720928269
pubmed: 32822230
pmcid: 7576920
Abend NA, Dlugos DJ. Treatment of refractory status epilepticus: literature review and a proposed protocol. Pediatr Neurol. 2008;38(6):377–90.
doi: 10.1016/j.pediatrneurol.2008.01.001
pubmed: 18486818
Prisco L, Ganau M, Aurangzeb S, et al. A pragmatic approach to intravenous anaesthetics and electroencephalographic endpoints for the treatment of refractory and super-refractory status epilepticus in critical care. Seizure. 2019;2020(75):153–64. https://doi.org/10.1016/j.seizure.2019.09.011 .
doi: 10.1016/j.seizure.2019.09.011
Wilkes R, Tasker RC. Intensive care treatment of uncontrolled status epilepticus in children: systematic literature search of midazolam and anesthetic therapies. Pediatr Crit Care Med. 2014;15(7):632–9. https://doi.org/10.1097/PCC.0000000000000173 .
doi: 10.1097/PCC.0000000000000173
pubmed: 24901802
Tasker RC, Goodkin HP, Fernandez IS, et al. Refractory status epilepticus in children: intention-to-treat with continuous infusions of midazolam and pentobarbital. Pediatr Crit Care Med. 2016;17(10):968–75. https://doi.org/10.1097/PCC.0000000000000900.Refractory .
doi: 10.1097/PCC.0000000000000900.Refractory
pubmed: 27500721
pmcid: 5052105
Vasquez A, Farias-Moeller R, Sánchez-Fernández I, et al. Super-refractory status epilepticus in children: a retrospective cohort study. Pediatr Crit Care Med. 2021;22(12):e613–25. https://doi.org/10.1097/pcc.0000000000002786 .
doi: 10.1097/pcc.0000000000002786
pubmed: 34120133
Tasker RC, Vitali SH. Continuous infusion, general anesthesia and other intensive care treatment for uncontrolled status epilepticus. Curr Opin Pediatr. 2014;26(6):682–9. https://doi.org/10.1097/MOP.0000000000000149 .
doi: 10.1097/MOP.0000000000000149
pubmed: 25313975
Keros S, Buraniqi E, Alex B, et al. Increasing ketamine use for refractory status epilepticus in US pediatric hospitals. J Child Neurol. 2017;32(7):638–46. https://doi.org/10.1177/0883073817698629 .
doi: 10.1177/0883073817698629
pubmed: 28349774
Akeju O, Song AH, Hamilos AE, et al. Electroencephalogram signatures of ketamine-induced unconsciousness. Clin Neurophysiol. 2016;127(6):2414–22. https://doi.org/10.1016/j.clinph.2016.03.005 .
doi: 10.1016/j.clinph.2016.03.005
pubmed: 27178861
pmcid: 4871620
Coles L, Rosenthal ES, Bleck TP, et al. Why Ketamine. Epilepsy Behav. 2023;5:141.
Jacobwitz M, Mulvihill C, Kaufman MC, et al. Ketamine for management of neonatal and pediatric refractory status epilepticus. Neurology. 2022;99(12):6.
doi: 10.1212/WNL.0000000000200889
Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American epilepsy society. Epilepsy Curr. 2016;16(1):48–61. https://doi.org/10.5698/1535-7597-16.1.48 .
doi: 10.5698/1535-7597-16.1.48
pubmed: 26900382
pmcid: 4749120
Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23. https://doi.org/10.1007/s12028-012-9695-z .
doi: 10.1007/s12028-012-9695-z
pubmed: 22528274
Buratti S, Giacheri E, Palmieri A, et al. Ketamine as advanced second-line treatment in benzodiazepine-refractory convulsive status epilepticus in children. Epilepsia. 2023;64:797–810. https://doi.org/10.1111/epi.17550 .
doi: 10.1111/epi.17550
pubmed: 36792542
Herman ST, Abend NS, Bleck TP, et al. Consensus statement on continuous EEG in critically Ill adults and children, Part II: personnel, technical specifications, and clinical practice. J Clin Neurophysiol. 2015;32(2):96–108. https://doi.org/10.1097/WNP.0000000000000165 .
doi: 10.1097/WNP.0000000000000165
pubmed: 25626777
pmcid: 4434600
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. https://doi.org/10.1016/j.jbi.2008.08.010 .
doi: 10.1016/j.jbi.2008.08.010
pubmed: 18929686
Witzman S, Massey SL, Kessler S, et al. Acceptability of standardized EEG reporting in an electronic health record. J Clin Neurophysiol. 2020;37(5):455–61. https://doi.org/10.1097/WNP.0000000000000639 .
doi: 10.1097/WNP.0000000000000639
pubmed: 31688354
pmcid: 7186141
Hirsch LJ, LaRoche SM, Gaspard N, et al. American Clinical Neurophysiology Society’s standardized critical care EEG terminology: 2012 version. J Clin Neurophysiol. 2013;30(1):1–27.
doi: 10.1097/WNP.0b013e3182784729
pubmed: 23377439
NINDS Common Data Elements Detailed Report for Adverse Events. https://www.commondataelements.ninds.nih.gov/cde_detailed_report/22914/Adverse Events/Safety Data/content/welcome. Accessed 1 May 2023
U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE).; 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
Fung FW, Jacobwitz M, Vala L, et al. Electroencephalographic seizures in critically Ill children: management and adverse effects. Epilepsia. 2019;60(10):2095–104. https://doi.org/10.1053/j.gastro.2016.08.014.CagY .
doi: 10.1053/j.gastro.2016.08.014.CagY
pubmed: 31538340
pmcid: 6786930
Traube C, Silver G, Kearney J, et al. Cornell assessment of pediatric delirium: a valid, rapid, observational tool for screening delirium in the PICU*. Crit Care Med. 2014;42(3):656–63. https://doi.org/10.1097/CCM.0b013e3182a66b76.Cornell .
doi: 10.1097/CCM.0b013e3182a66b76.Cornell
pubmed: 24145848
pmcid: 5527829
Franck LS, Harris SK, Soetenga DJ, Amling JK, Curley MAQ. The withdrawal assessment tool-version 1 (WAT-1): an assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients. Pediatr Crit Care Med. 2008;9(6):573–80. https://doi.org/10.1097/PCC.0b013e31818c8328.The .
doi: 10.1097/PCC.0b013e31818c8328.The
pubmed: 18838937
pmcid: 2775493
Rosati A, De Masi S, Guerrini R. Ketamine for refractory status epilepticus: a systematic review. CNS Drugs. 2018;32:997–1009.
doi: 10.1007/s40263-018-0569-6
pubmed: 30232735
Huntsman RJ, Strueby L, Bingham W. Are ketamine infusions a viable therapeutic option for refractory neonatal seizures? Pediatr Neurol. 2020;103:8–11.
doi: 10.1016/j.pediatrneurol.2019.09.003
pubmed: 31601453
Wu J, Wang Q, Qian SY, et al. Effectiveness of ketamine in the treatment of refractory and super-refractory status epilepticus in children. Chin J Pediatr. 2020;58(4):295–300.
Rosati A, Ilvento L, L’Erario M, et al. Efficacy of ketamine in refractory convulsive status epilepticus in children: a protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01). BMJ Open. 2016;6(6):1–6. https://doi.org/10.1136/bmjopen-2016-011565 .
doi: 10.1136/bmjopen-2016-011565
Golub D, Yanai A, Darzi K, Papadopoulos J, Kaufman B. Potential consequences of high-dose infusion of ketamine for refractory status epilepticus: case reports and systematic literature review. Anaesth Intensive Care. 2018;46(5):516–28. https://doi.org/10.1177/0310057X1804600514 .
doi: 10.1177/0310057X1804600514
pubmed: 30189827
Höfler J, Trinka E. Intravenous ketamine in status epilepticus. Epilepsia. 2018;59(August):198–206. https://doi.org/10.1111/epi.14480 .
doi: 10.1111/epi.14480
pubmed: 30146731
Ilvento L, Rosati A, Marini C, L’Erario M, Mirabile L, Guerrini R. Ketamine in refractory convulsive status epilepticus in children avoids endotracheal intubation. Epilepsy Behav. 2015;49:343–6.
doi: 10.1016/j.yebeh.2015.06.019
pubmed: 26189786
Rosati A, L’Erario M, Ilvento L, et al. Efficacy and safety of ketamine in refractory status epilepticus in children. Neurology. 2012;79(24):2355–8. https://doi.org/10.1212/WNL.0b013e318278b685 .
doi: 10.1212/WNL.0b013e318278b685
pubmed: 23197747
Gaspard N, Foreman B, Judd LM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multi-center study. Epilepsia. 2013;54(8):1498–503. https://doi.org/10.1111/epi.12247.Intravenous .
doi: 10.1111/epi.12247.Intravenous
pubmed: 23758557
pmcid: 3731413
Morrison G, Gibbons E, Whitehouse WP. High-dose midazolam therapy for refractory status epilepticus in children. Intensive Care Med. 2006;32(12):2070–6. https://doi.org/10.1007/s00134-006-0362-8 .
doi: 10.1007/s00134-006-0362-8
pubmed: 16977485
Blumer JL. Clinical pharmacology of Midazolam in infants and children. Science. 1998;35(1):37–47.
Sperotto F, Giaretta I, Mondardini MC, Pece F, Daverio M, Amigoni A. Ketamine prolonged infusions in the pediatric intensive care unit: a tertiary-care single-center analysis. J Pediatr Pharmacol Ther. 2021;26(1):73–80. https://doi.org/10.5863/1551-6776-26.1.73 .
doi: 10.5863/1551-6776-26.1.73
pubmed: 33424503
pmcid: 7792146
Alkhachroum A, Der-Nigoghossian CA, Mathews E, et al. Ketamine to treat super-refractory status epilepticus. Neurology. 2020;95(16):69.
doi: 10.1212/WNL.0000000000010611
Fung FW, Parikh DS, Massey SL, et al. Periodic and rhythmic patterns in critically ill children: incidence, interrater agreement, and seizures. Epilepsia. 2021;62(12):2955–67. https://doi.org/10.1111/epi.17068 .
doi: 10.1111/epi.17068
pubmed: 34642942
Hirsch LJ, Fong MWK, Leitinger M, et al. American Clinical Neurophysiology Society’s standardized critical Care EEG terminology: 2021 version. J Clin Neurophysiol. 2021;38(1):1–29.
doi: 10.1097/WNP.0000000000000806
pubmed: 33475321
pmcid: 8135051